ci 988 has been researched along with bethanechol in 1 studies
| Studies (ci 988) | Trials (ci 988) | Recent Studies (post-2010) (ci 988) | Studies (bethanechol) | Trials (bethanechol) | Recent Studies (post-2010) (bethanechol) |
|---|---|---|---|---|---|
| 147 | 8 | 14 | 988 | 53 | 87 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akuzawa, S; Ito, H; Kamato, T; Katuyama, Y; Kobayashi, A; Miyata, K; Nishida, A; Tsutsumi, R; Yamano, M; Yuki, H | 1 |
1 other study(ies) available for ci 988 and bethanechol
| Article | Year |
|---|---|
Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Topics: Animals; Benzodiazepines; Benzodiazepinones; Bethanechol; Bethanechol Compounds; Gastric Acid; Gastric Mucosa; Histamine; In Vitro Techniques; Indoles; Male; Meglumine; Pentagastrin; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Sincalide | 1994 |